Can T-DXd Change Early HER2+ Breast Cancer Forever? – Dr. Ruta Rao & Dr. VK Gadi

In this expert discussion, Dr. VK Gadi and Dr. Ruta Rao break down the data that’s reshaping treatment for HER2-positive breast cancer — from DESTINY-Breast 05 and 11 to the first-line metastatic implications of DESTINY-Breast 09.

They explore what the numbers really mean for patients with residual disease, how CNS risk and toxicity factor into decision-making, and where T-DXd may (or may not) replace existing standards of care.

A candid, data-driven conversation for clinicians navigating HER2+ treatment today — and preparing for what comes next.